Sepsis News and Research

Latest Sepsis News and Research

Study finds reductions in hospital admissions for childhood infections during first year of pandemic

During the first year or so of the covid-19 pandemic, there were dramatic reductions in hospital admissions for common and severe childhood infections in England, most likely due to social distancing measures, school and workplace closures, and travel restrictions, finds a study published by The BMJ today.

13 Jan 2022

Mapping peripheral blood glycoprotein profiles of COVID-19 patients

A team of researchers recently analyzed differential protein glyco-isoform distributions of symptomatic and asymptomatic coronavirus disease 2019 patients.

11 Jan 2022

Study shows probiotics can reduce symptoms of COVID-19 when taken post-exposure

A new study shows how a daily use of Lactobacillus rhamnosus GG (LGG) probiotic may protect against symptom development in instances when it is used as post-exposure prophylaxis within seven days after exposure to severe acute respiratory syndrome coronavirus 2.

7 Jan 2022

Structural blueprint of nanoparticles developed to target neutrophils responsible for acute lung inflammation

The COVID-19 pandemic highlighted the devastating impact of acute lung inflammation (ALI), which is part of the acute respiratory distress syndrome (ARDS) that is the dominant cause of death in COVID-19.

28 Dec 2021

Pediatric hospital admissions rise with omicron SARS-CoV-2 variant

A new study examines the impact of the Omicron variant on hospitalizations among children in South Africa.

23 Dec 2021

Driving up immunity at tumor site may help enhance immunotherapy treatments

Driving up the immune response at the site of a cancer tumor with nanotechnology may help enhance immunotherapy treatments in advanced stages of the disease, new research in mice suggests.

14 Dec 2021

WHO and UNICEF warn about the lack of basic water services in health care facilities

Around 1.8 billion people are at heightened risk of COVID-19 and other diseases because they use or work in health care facilities without basic water services, warn WHO and UNICEF.

14 Dec 2021

Severity of SARS-CoV-2 compared to other human coronaviruses in children

Researchers observed that symptom presentation of SARS-CoV-2 infections at the community level was very similar to that of endemic human coronavirus infections.

14 Dec 2021

Nasal infection drives lethal lung injury due to SARS-CoV-2 in mice

A new study demonstrates lethal infection of the olfactory epithelium in a mouse model that could help understand the mechanisms of COVID-19.

12 Dec 2021

Machine-learning model could help identify treatments that pose higher risk than other options

Sepsis claims the lives of nearly 270,000 people in the U.S. each year. The unpredictable medical condition can progress rapidly, leading to a swift drop in blood pressure, tissue damage, multiple organ failure, and death.

11 Dec 2021

UEA researchers reveal how immune cells use the body’s fat stores to fight infection

New research from the University of East Anglia and Quadram Institute reveals how our immune cells use the body’s fat stores to fight infection.

9 Dec 2021

AI-based technology to identify patients at risk of serious illness as a result of blood infections

A new technology developed at Tel Aviv University will make it possible, using artificial intelligence, to identify patients who are at risk of serious illness as a result of blood infections.

8 Dec 2021

Hypercoagulability of the blood responsible for cardiac thrombosis in COVID-19 patients

Researchers examined autopsy tissue samples of hearts from patients who died early in the COVID-19 pandemic.

7 Dec 2021

Octapharma USA announces FDA approval of cutaquig 16.5% for pediatric PI patients

Octapharma USA today announced the U.S. Food & Drug Administration has approved cutaquig [Immune globulin, Subcutaneous (Human)-hipp, 16.5% Solution] for the treatment of pediatric patients age 2 and older with primary humoral immunodeficiency (PI). The FDA previously approved cutaquig for adults with PI.

7 Dec 2021

Poolbeg and University College Dublin sign an Option Agreement to license melioidosis vaccine candidate

Poolbeg Pharma, 'Poolbeg' or the 'Company', a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has signed an Option Agreement to licence MelioVac, a vaccine for melioidosis, with University College Dublin and its inventor, Associate Professor Siobhán McClean, through NovaUCD, the university's knowledge transfer office.

7 Dec 2021

Sepsis News and Research

Latest Sepsis News and Research

Study finds reductions in hospital admissions for childhood infections during first year of pandemic

Mapping peripheral blood glycoprotein profiles of COVID-19 patients

Study shows probiotics can reduce symptoms of COVID-19 when taken post-exposure

Structural blueprint of nanoparticles developed to target neutrophils responsible for acute lung inflammation

Pediatric hospital admissions rise with omicron SARS-CoV-2 variant

Driving up immunity at tumor site may help enhance immunotherapy treatments

WHO and UNICEF warn about the lack of basic water services in health care facilities

Severity of SARS-CoV-2 compared to other human coronaviruses in children

Nasal infection drives lethal lung injury due to SARS-CoV-2 in mice

Machine-learning model could help identify treatments that pose higher risk than other options

UEA researchers reveal how immune cells use the body’s fat stores to fight infection

AI-based technology to identify patients at risk of serious illness as a result of blood infections

Hypercoagulability of the blood responsible for cardiac thrombosis in COVID-19 patients

Octapharma USA announces FDA approval of cutaquig 16.5% for pediatric PI patients

Poolbeg and University College Dublin sign an Option Agreement to license melioidosis vaccine candidate

Using metal nanoparticles to fight SARS-CoV-2

New AI predictive algorithm greatly improves timeliness and accuracy of sepsis predictions

Oral Hsp90 inhibitor SNX-5422 interferes with replication machinery of SARS-CoV-2

Does SARS-CoV-2 infection contribute to adrenal gland dysfunction?

UC researchers engineer new probiotic to target and break down cancer cell defenses

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Sepsis News and Research

Latest Sepsis News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in